



12 October 2005

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

Dear Sir,

First European Patent Granted

The Resonance Health Group (ASX: RHT) is pleased to announce that it has been granted its first patent in the important European market.

European Patent 1,218,766 describes and protects the core invention underlying the FerriScan® test for the non-invasive measurement of liver iron concentration. This patent is the European equivalent to the US Patent 6,605,943 which was granted in 2003 and which is also being prosecuted in several other jurisdictions.

“The granting of the European Patent for the cornerstone of our technology platform confirms its novelty and secures our monopoly in the large European market” said Resonance Health Managing Director Dr James Williams. “The combination of having granted patents, completed major regulatory clearances and being first to market strengthens Resonance Health’s position as the leader in the commercial application of MRI for the non-invasive measurement of liver iron concentration” he continued.


Resonance Health is also prosecuting a second patent family which further expands the company’s technology platform, and, in addition, continues various Research & Development programs which have the potential to further expand the scope of the company’s intellectual property assets.

Following the completion of the acquisition of Inner Vision Biometrics Pty Ltd in May 2005, Resonance Health owns, royalty free, 100% of the intellectual property assets relating to the FerriScan test.

Further information:

About ‘Iron Overload’ Conditions

Having too much iron in the body and being unable to get rid of this excess is one of the world’s most common hereditary disorders. The disorders, often collectively termed as ‘Iron Overload’, are generally classified as primary (e.g. hereditary hemochromatosis – HHC) or secondary (e.g. acquired – transfusional iron overload such as thalassemia). Approximately



11 million people globally, who have 'clinically significant' iron loading would benefit from improved diagnosis and management of their condition.

Hemochromatosis is a genetic disorder that causes iron deposition in the liver and other organs of the body, resulting in iron overload. The condition frequently remains undiagnosed because of lack of awareness, its long latency period and its non-specific symptoms. Thalassaemia, a genetic blood disorder and a very severe and debilitating form of anaemia, also results in iron overload due to the requirement for frequent blood transfusions.

About Resonance Health Ltd

Resonance Health (ASX: RHT) is an Australian Healthcare company specialising in the development and commercialisation of magnetic resonance imaging (MRI) related technology for the quantitative measurement of iron levels in the human body.

Our mission is to develop and market our technologies to assist in the diagnosis and management of patients suffering from iron-related conditions, whilst delivering significant added value for our MRI customers who deliver our service through their networks.

In 2005, RHT began the global commercial launch of FerriScan®, its world leading non-invasive tool for measuring liver iron levels.

The FerriScan service involves an MRI scan followed by off-site processing of the images by RHT using its patented methodology to generate the liver iron concentration result. MR data is transmitted electronically via a secure data process to the RHT analysis centre from anywhere in the world. The test requires no new equipment purchase at the MRI centre level.

FerriScan provides a significant improvement over current blood markers and invasive surgical procedures. This improvement leads to increased clinical efficiency and accuracy in diagnosis, in addition to allowing optimisation of treatment programs for iron-related disorders. FerriScan is now positioned to become a routine part of the clinical diagnosis and management of iron loading disorders as well as playing a major role in the testing and monitoring of drugs used to treat these conditions.

FerriScan has received regulatory clearance to be marketed in the USA, Australia, UK and Europe. Further information about Resonance Health and FerriScan® can be obtained from the following websites: www.resonancehealth.com and www.ferriscan.com.

Media and Investor Relations	Resonance Health
Rebecca Piercy Buchan Consulting T - +61 3 9866 4722 M – 0422 916 422 Email: rpiercy@bcg.com.au	Dr James Williams Managing Director Resonance Health Limited T - +61 8 9286 5300 M - 0409 050 519 Email: jamesw@ferriscan.com